LabCorp(R) Scheduled to Present at UBS Warburg Global Life Sciences Conference

BURLINGTON, N.C., Oct 10, 2001 /PRNewswire via COMTEX/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that Thomas P. Mac Mahon, chairman and chief executive officer, is scheduled to speak at the UBS Warburg Global Life Sciences Conference in New York City,

LabCorp's National Genetics Institute Receives FDA Approval for Nucleic Acid Tests for HCV and HIV-1

BURLINGTON, N.C., Sep 21, 2001 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that its National Genetics Institute Inc. (NGI) had its Biologics License Applications for the UltraQual(TM) HCV RT-PCR and UltraQual(TM) HIV-1 RT-PCR assays approved

Laboratory Corporation of America(R) Holdings Announces Completion of Private Placement

BURLINGTON, N.C., Sept. 19 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today confirmed that it had previously completed its private placement of zero coupon convertible subordinated notes due 2021, the effect of which is expected to be accretive to 2001

Laboratory Corporation of America(R) Holdings Sets Terms of Zero Coupon Convertible Subordinated Notes

BURLINGTON, N.C., Sept. 6 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the terms of its private placement of zero coupon convertible subordinated notes due 2021 with an aggregate principal amount at maturity of $650 million.

Laboratory Corporation of America(R) Holdings Announces Offering Of Zero Coupon Convertible Subordinated Notes

BURLINGTON, N.C., Sep 4, 2001 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced its intention, subject to market and other conditions, to raise approximately $435 million (excluding proceeds of an overallotment option, if any) through a private

Alpha Therapeutic Forms Alliance for Plasma Testing Laboratory; Agreement With National Genetics Institute and LabCorp Enhances Testing Operations

LOS ANGELES, Aug 28, 2001 (BW HealthWire) -- Alpha Therapeutic Corporation announced today that it has formed a laboratory management alliance with National Genetics Institute (NGI), a subsidiary of Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH), in which NGI/LabCorp will

Laboratory Corporation of America(R) Announces Second Quarter Results; Continued Price and Volume Gains Generate Record Profits

BURLINGTON, N.C., Jul 23, 2001 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced results for the quarter ended June 30, 2001. Second Quarter Results Net sales were $549.7 million, operating income was $102.6 million, and net income was $52.1

EXACT Sciences and Laboratory Corporation of America Sign Licensing Agreement For Testing Services Based Upon EXACT Sciences' Genomics-Based Technologies

BURLINGTON, N.C., July 11 /PRNewswire/ -- EXACT Sciences Corporation (Nasdaq: EXAS) and Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that they have signed an agreement for the licensing of EXACT Sciences' proprietary genomics- based technologies to LabCorp.

LabCorp(R) Scheduled to Present at Goldman, Sachs & Co. Healthcare Conference

BURLINGTON, N.C., Jun 12, 2001 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that Bradford T. Smith, executive vice president of public affairs, is scheduled to speak at the Goldman, Sachs & Co. Healthcare Conference in Dana Point, CA on

LabCorp(R) Acquires ViroMed Inc.

BURLINGTON, N.C., June 4 /PRNewswire/ -- Laboratory Corporation of America Holdings (NYSE: LH) (LabCorp(R)) today announced that it has completed the acquisition of Minneapolis-based ViroMed Inc. ViroMed had clinical laboratory revenues for the twelve months ended December 31, 2000 of approximately